|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0035696,
umls-concept:C0079925,
umls-concept:C0201734,
umls-concept:C0205390,
umls-concept:C0205460,
umls-concept:C0246415,
umls-concept:C0376358,
umls-concept:C0376515,
umls-concept:C0935954,
umls-concept:C1144384,
umls-concept:C1258613,
umls-concept:C1511524
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2004-8-6
|
|
pubmed:abstractText |
To assess the feasibility of administering oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the Bcl-2 mRNA, with docetaxel to patients with hormone-refractory prostate cancer; to characterize the pertinent pharmacokinetic parameters, Bcl-2 protein inhibition in peripheral blood mononuclear cell(s) (PBMC) and tumor; and to seek preliminary evidence of antitumor activity.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Oligonucleotides, Antisense,
http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/Thionucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/oblimersen
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BushnellDavidD,
pubmed-author:FingertHowardH,
pubmed-author:HammondLisa ALA,
pubmed-author:IzbickaElzbietaE,
pubmed-author:KreisbergJeffreyJ,
pubmed-author:KuhnJohnJ,
pubmed-author:MalikShazliS,
pubmed-author:PatnaikAmitaA,
pubmed-author:RowinskyEric KEK,
pubmed-author:SchwartzGarryG,
pubmed-author:SmetzerLeslieL,
pubmed-author:ThompsonIanI,
pubmed-author:TolcherAnthony WAW
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5048-57
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15297406-Aged,
pubmed-meshheading:15297406-Antineoplastic Agents,
pubmed-meshheading:15297406-Area Under Curve,
pubmed-meshheading:15297406-Biopsy,
pubmed-meshheading:15297406-Dose-Response Relationship, Drug,
pubmed-meshheading:15297406-Drug Resistance, Neoplasm,
pubmed-meshheading:15297406-Humans,
pubmed-meshheading:15297406-Immunohistochemistry,
pubmed-meshheading:15297406-Infusions, Intravenous,
pubmed-meshheading:15297406-Leukocytes, Mononuclear,
pubmed-meshheading:15297406-Male,
pubmed-meshheading:15297406-Middle Aged,
pubmed-meshheading:15297406-Oligonucleotides, Antisense,
pubmed-meshheading:15297406-Phosphorylation,
pubmed-meshheading:15297406-Prostate-Specific Antigen,
pubmed-meshheading:15297406-Prostatic Neoplasms,
pubmed-meshheading:15297406-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:15297406-RNA, Messenger,
pubmed-meshheading:15297406-Taxoids,
pubmed-meshheading:15297406-Thionucleotides,
pubmed-meshheading:15297406-Time Factors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
|
|
pubmed:affiliation |
Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas 78229, USA. atolcher@idd.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase I
|
